RAD51 and Fanconi anemia: Clinically, HRR defects extend beyond BRCA1/2, encompassing PALB2, BARD1, RAD51 paralogs and Fanconi anemia genes; RAD51 foci assays are emerging as functional biomarkers to guide PARP inhibitor use and combination strategies [30,31,32].